Observational studyFrontiers in immunology2025

Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.

Takaya Tabuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.